Knowledge and Attitudes About Screening and Preventive Treatment of Latent Tuberculosis Infection Among Patients with Rheumatic Diseases in Beijing, China.

Infect Drug Resist

Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

Published: August 2024

AI Article Synopsis

  • The study focuses on how to improve tuberculosis preventive treatment (TPT) compliance among patients with rheumatic diseases (RD), who are at higher risk for developing active TB.
  • Researchers recruited 200 RD outpatients to complete questionnaires assessing their knowledge and attitudes towards latent TB infection (LTBI) screening and TPT.
  • Findings suggested that tertiary education and personal risk perceptions influenced patients' willingness to participate in screenings and treatments, while many expressed difficulty with the idea of taking multiple pills daily; educating both patients and rheumatologists could enhance compliance.

Article Abstract

Objective: Tuberculosis preventive treatment (TPT) is an important strategy for tuberculosis (TB) control. Rheumatic diseases (RD) patients are at high risk for active TB development. More researches are needed in terms of patient compliance in clinical practice. This study aims to explore the potential difficulties and obstacles in latent tuberculosis infection (LTBI) screening and TPT in RD patients.

Methods: Convenience sampling was used to recruit RD outpatients who had indications for LTBI screening and TPT. All participants were given questionnaires on knowledge and attitudes regarding screening and preventive treatment of LTBI.

Results: Of the 200 RD patients, most people were aware that they were at increased risk of ATB due to their rheumatic disease and knew that TB was curable. The main association with willingness to have screening for LTBI was tertiary education ( = 0.013). The main association with willingness to take treatment for LTBI was a sense of personal risk and belief that the treatment would reduce risk of ATB ( < 0.001). More than half of the people surveyed could not accept taking 6 or more pills per day, while more than half of the patients could tolerate a treatment course of 9 months or longer. Most (65.4%) preferred their own rheumatologists to initiate treatment.

Conclusion: Educating RD patients about their individual risks of TB and the side effects of treatment, and educating/empowering rheumatologists to discuss these aspects with their patients and to offer LTBI screening and treatment, may help improve patients' compliance with LTBI screening and TPT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317057PMC
http://dx.doi.org/10.2147/IDR.S471448DOI Listing

Publication Analysis

Top Keywords

ltbi screening
16
preventive treatment
12
screening tpt
12
knowledge attitudes
8
attitudes screening
8
screening preventive
8
treatment
8
latent tuberculosis
8
tuberculosis infection
8
rheumatic diseases
8

Similar Publications

Background: Identifying patients with latent tuberculosis infection (LTBI) is challenging. This is particularly true amongst immunocompromised hosts, in whom the diagnostic accuracy of available tests is limited. The authors evaluated the impact of routine pretransplant review by a transplant infectious diseases (TID) physician on LTBI screening in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients.

View Article and Find Full Text PDF

Clinical value of serum miRNA-206 in pulmonary tuberculosis.

J Infect Chemother

December 2024

Tuberculosis Department, Huai'an No.4 People's Hospital, Huaian 223000, Jiangsu Province, China. Electronic address:

Objective: This study sought to investigate the diagnostic value and the effect of microRNA (miR)-206 on drug resistance in pulmonary tuberculosis (TB) patients.

Methods: This study included 88 TB patients (TB group) as study subjects, 80 healthy subjects as control 1 (Control group), and 85 latent TB infection (LTBI) patients as control 2 (LTBI group). The drug resistance of TB patients after standard anti-TB treatment was recorded.

View Article and Find Full Text PDF

Tuberculosis in adult migrants in Europe: a TBnet consensus statement.

Eur Respir J

December 2024

Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.

Introduction: Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. Migrants' risk of tuberculosis (TB) differs by reasons for migration, socioeconomic status, mode of travel and TB risk in transit, TB incidence and healthcare provision in country of origin. Despite advances in TB care for migrants and new treatment strategies, decisions for the management of migrants at risk of TB often rely on expert opinions, rather than clinical evidence.

View Article and Find Full Text PDF

Latent Tuberculosis Infection (LTBI) is a state of persistent immune response to complex antigens without clinical, radiological and microbiological signs of active disease. Effective diagnosis and preventive treatment of LTBI are crucial for tuberculosis (TB) control, especially in high-risk groups. Currently, two main tests are used for LTBI diagnosis: the Tuberculin Skin Test (TST) and the Interferon-Gamma Release Assays (IGRA), including the QuantiFERON-TB Gold Plus (QFT-Plus) and the T-SPOT.

View Article and Find Full Text PDF

Individuals with hematologic malignancy have increased risk of latent tuberculosis infection (LTBI) reactivation and (SS) dissemination. However, screening prior to chemotherapy or corticosteroids is not routine. We conducted a LTBI and SS screening intervention amongst patients with hematologic malignancies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!